Carregant...

CSPG4-Specific CAR T Cells for High-Risk Childhood B Cell Precursor Leukemia

The advent of CD19-specific chimeric antigen receptor (CAR) T cells has proven to be a powerful asset in the arsenal of cancer immunotherapy of acute lymphoblastic leukemia and certain B cell lymphomas. However, a sizable portion of patients treated with CD19-CAR T cells relapse with CD19-negative c...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Int J Mol Sci
Autors principals: Harrer, Dennis C., Schuler, Gerold, Dörrie, Jan, Schaft, Niels
Format: Artigo
Idioma:Inglês
Publicat: MDPI 2019
Matèries:
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6600602/
https://ncbi.nlm.nih.gov/pubmed/31195686
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ijms20112764
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!